Translational Research in Oncology (TRIO) Enrolls First Patient in Early Breast Cancer Phase II Trial

Translational Research in Oncology announced enrolment of the first patient in a Phase II randomized, multi-center, open-label clinical trial of GDC-9545 sponsored by F. Hoffmann-La Roche.
[Translational Research in Oncology (Globe Newswire)]
Press Release
Bookmark

No account yet? Register

0
Share

Production, Safety and Efficacy of iPSC-Derived Mesenchymal Stromal Cells in Acute Steroid-Resistant Graft versus Host Disease: A Phase I, Multicenter, Open-Label, Dose-Escalation Study

Researchers assessed the safety and tolerability of CYP-001 (iPSC-derived MSCs), while the secondary objectives were to evaluate efficacy based on the proportion of participants who showed a complete response , overall response and overall survival by days 28/100.
[Nature Medicine]
Bloor, A. J. C., Patel, A., Griffin, J. E., Gilleece, M. H., Radia, R., Yeung, D. T., Drier, D., Larson, L. S., Uenishi, G. I., Hei, D., Kelly, K., Slukvin, I., & Rasko, J. E. J. (2020). Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nature Medicine, 1–6. https://doi.org/10.1038/s41591-020-1050-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase III Trial in Second-line Pancreatic Cancer Nears Complete Enrollment

Erytech Pharma has announced the hosting of a Key Opinion Leader (KOL) event to discuss the medical need in pancreatic cancer and the potential role of eryaspase in this setting. TRYbeCA-1, the pivotal Phase III clinical trial evaluating Erytech’s lead product candidate, eryaspase, in second-line metastatic pancreatic cancer, has randomized more than 450 of the approximately 500 patients to be enrolled in the trial.
[Erytech Pharma Inc. (GlobeNewswire Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Major ‘plasmaMATCH’ Trial Uses Blood Test to Match Women With Breast Cancer to Range of Precision Treatments

A blood test identified a variety of mutations in advanced breast cancer could reliably match women to effective targeted treatments, early results of a major clinical trial revealed.
[The Institute of Cancer Research]
Press Release
Bookmark

No account yet? Register

0
Share

ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01

ImCheck Therapeutics announced that the independent Safety Review Committee for the EVICTION Phase I/II clinical trial for its lead antibody ICT01 unanimously approved dose escalation in the solid tumor indications and the start of enrollment in the two other arms of the study: treatment with ICT01 in patients with hematologic malignancies as monotherapy and in solid tumor patients in combination with pembrolizumab.
[ImCheck Therapeutics]
Press Release
Bookmark

No account yet? Register

0
Share

ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01

ImCheck Therapeutics announced that the independent Safety Review Committee for the EVICTION Phase I/II clinical trial for its lead antibody ICT01 unanimously approved dose escalation in the solid tumor indications and the start of enrollment in the two other arms of the study.
[ImCheck Therapeutics]
Press Release
Bookmark

No account yet? Register

0
Share

VBL Therapeutics Announces Enrollment of the First Patients in the Phase II Clinical Trial of VB-111 in Metastatic Colorectal Cancer

VBL Therapeutics announced that the first two patients have been enrolled in the Phase II clinical trial of VB-111 in combination with nivolumab, an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer.
[VBL Therapeutics]
Press Release
Bookmark

No account yet? Register

0
Share

Boehringer Ingelheim Advances Novel Bi-Specific TRAILR2/CDH17 Antibody to Phase I Clinical Trial for Patients Living with Gastrointestinal Cancers

Boehringer Ingelheim announced the advancement of the bi-specific and tetravalent therapeutic antibody, BI 905711, to its first-in-human clinical trial for patients with advanced gastrointestinal cancers.
[Boehringer Ingelheim International GmbH]
Press Release
Bookmark

No account yet? Register

0
Share

5-Fluorouracil Enhances the Anti-Tumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers

Investigators report that the glutaminase inhibitor CB-839 preferentially inhibited xenograft growth of PIK3CA-mutant, but not wild-type, colorectal cancer. Moreover, the combination of CB-839 and 5-fluorouracil induces PIK3CA-mutant tumor regression in xenograft models.
[Cancer Research]
Abstract
Bookmark

No account yet? Register

0
Share

PRA Health Sciences Joins The Leukemia & Lymphoma Society on Global Trial for Children with Acute Leukemia

The Leukemia & Lymphoma Society and PRA Health Sciences announced a partnership to launch a first-of-its-kind global master clinical trial to develop new treatments for children with relapsed acute leukemia.
[The Leukemia & Lymphoma Society (PRNewswire,LLC)]
Press Release
Bookmark

No account yet? Register

0
Share

Celularity Doses First Patient in Clinical Trial Evaluating CYNK-001 in COVID-19 Patients

Celularity announced that the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells for the treatment of adults with COVID-19 as part of a national clinical trial.
[Celularity Inc.]
Press Release
Bookmark

No account yet? Register

0
Share
Share